
Teladoc Health (TDOC) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
629.4M
Gross Profit
432.5M
68.73%
Operating Income
-54.9M
-8.73%
Net Income
-93.0M
-14.78%
EPS (Diluted)
$-0.53
Balance Sheet Metrics
Total Assets
2.9B
Total Liabilities
1.5B
Shareholders Equity
1.4B
Debt to Equity
1.03
Cash Flow Metrics
Operating Cash Flow
89.6M
Free Cash Flow
31.6M
Revenue & Profitability Trend
Teladoc Health Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 2.6B | 2.6B | 2.4B | 2.0B | 1.1B |
Cost of Goods Sold | 751.3M | 760.0M | 744.0M | 650.3M | 390.8M |
Gross Profit | 1.8B | 1.8B | 1.7B | 1.4B | 703.1M |
Gross Margin % | 70.8% | 70.8% | 69.1% | 68.0% | 64.3% |
Operating Expenses | |||||
Research & Development | 307.3M | 348.5M | 333.6M | 311.9M | 164.9M |
Selling, General & Administrative | 1.3B | 1.4B | 1.3B | 1.1B | 886.9M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 1.7B | 1.7B | 1.6B | 1.4B | 1.1B |
Operating Income | -208.8M | -210.5M | -227.4M | -239.0M | -418.2M |
Operating Margin % | -8.1% | -8.1% | -9.4% | -11.8% | -38.2% |
Non-Operating Items | |||||
Interest Income | 57.1M | 46.8M | 12.7M | 776.0K | - |
Interest Expense | 23.8M | 22.3M | 21.9M | 81.1M | 60.0M |
Other Non-Operating Income | -818.1M | -33.6M | -13.4B | -65.3M | -97.9M |
Pre-tax Income | -993.7M | -219.6M | -13.7B | -384.7M | -576.0M |
Income Tax | 7.6M | 760.0K | -3.8M | 44.1M | -90.9M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -1.0B | -220.4M | -13.7B | -428.8M | -485.1M |
Net Margin % | -39.0% | -8.5% | -567.5% | -21.1% | -44.3% |
Key Metrics | |||||
EBITDA | 225.1M | 192.0M | 55.1M | -13.5M | -340.6M |
EPS (Basic) | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 |
EPS (Diluted) | $-5.87 | $-1.34 | $-84.60 | $-2.73 | $-5.36 |
Basic Shares Outstanding | 170564088 | 162169564 | 161457123 | 156939349 | 90509229 |
Diluted Shares Outstanding | 170564088 | 162169564 | 161457123 | 156939349 | 90509229 |
Income Statement Trend
Teladoc Health Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.3B | 1.1B | 918.2M | 893.5M | 733.3M |
Short-term Investments | - | - | 0 | 2.5M | 53.2M |
Accounts Receivable | 214.1M | 217.4M | 210.6M | 169.0M | 169.3M |
Inventory | 38.1M | 29.5M | 56.3M | 73.1M | 56.5M |
Other Current Assets | 2.8M | 7.4M | 12.1M | 5.7M | 47.3M |
Total Current Assets | 1.7B | 1.5B | 1.3B | 1.2B | 1.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 43.0M | 55.2M | 54.5M | 57.8M | 55.1M |
Goodwill | 2.0B | 3.8B | 4.0B | 30.9B | 31.2B |
Intangible Assets | 1.4B | 1.7B | 1.8B | 1.9B | 2.0B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 81.5M | 80.3M | 48.5M | 20.7M | 18.4M |
Total Non-Current Assets | 1.9B | 2.9B | 3.0B | 16.5B | 16.7B |
Total Assets | 3.5B | 4.4B | 4.3B | 17.7B | 17.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 33.1M | 43.6M | 47.7M | 47.3M | 46.0M |
Short-term Debt | 561.1M | 10.8M | 13.6M | 12.7M | 54.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 32.5M | 37.5M | 44.9M | 40.3M | 34.3M |
Total Current Liabilities | 941.5M | 420.6M | 399.8M | 331.0M | 332.6M |
Non-Current Liabilities | |||||
Long-term Debt | 1.0B | 1.6B | 1.6B | 1.3B | 1.4B |
Deferred Tax Liabilities | 49.9M | 49.5M | 50.9M | 75.8M | 102.1M |
Other Non-Current Liabilities | 720.0K | 1.1M | 1.6M | 10.8M | 11.5M |
Total Non-Current Liabilities | 1.1B | 1.6B | 1.6B | 1.4B | 1.5B |
Total Liabilities | 2.0B | 2.1B | 2.0B | 1.7B | 1.9B |
Equity | |||||
Common Stock | 173.0K | 167.0K | 163.0K | 160.0K | 150.0K |
Retained Earnings | -16.2B | -15.2B | -15.0B | -1.4B | -992.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.5B | 2.3B | 2.3B | 16.0B | 15.9B |
Key Metrics | |||||
Total Debt | 1.6B | 1.6B | 1.6B | 1.3B | 1.5B |
Working Capital | 722.4M | 1.1B | 915.6M | 894.4M | 727.0M |
Balance Sheet Composition
Teladoc Health Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -1.0B | -220.4M | -13.7B | -428.8M | -485.1M |
Depreciation & Amortization | 382.8M | 351.3M | 270.6M | 219.6M | 78.1M |
Stock-Based Compensation | 146.0M | 201.6M | 217.9M | 302.6M | 475.5M |
Working Capital Changes | -51.2M | -29.1M | -56.2M | -26.4M | -132.9M |
Operating Cash Flow | -515.0M | 304.6M | -13.2B | 166.2M | -110.3M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | - | 0 | 0 | -78.7M | -567.4M |
Investment Purchases | - | - | - | - | - |
Investment Sales | 0 | 0 | 2.5M | 60.9M | 2.5M |
Investing Cash Flow | 0 | 1.0K | 5.0M | -9.0M | -564.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | 0 | 0 | 1.0B |
Debt Repayment | - | - | 0 | -139.0K | -238.2M |
Financing Cash Flow | -2.0K | -278.0K | -5.9M | -1.8M | 800.1M |
Free Cash Flow | 169.6M | 193.7M | 16.5M | 130.1M | -79.6M |
Net Change in Cash | -515.0M | 304.3M | -13.2B | 155.4M | 124.9M |
Cash Flow Trend
Teladoc Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.31
Forward P/E
-8.63
Price to Book
0.95
Price to Sales
0.53
PEG Ratio
0.01
Profitability Ratios
Profit Margin
-8.16%
Operating Margin
-7.29%
Return on Equity
-14.18%
Return on Assets
-3.57%
Financial Health
Current Ratio
2.67
Debt to Equity
72.78
Beta
1.77
Per Share Data
EPS (TTM)
$-1.15
Book Value per Share
$8.05
Revenue per Share
$14.65
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
tdoc | 1.4B | -1.31 | 0.95 | -14.18% | -8.16% | 72.78 |
Veeva Systems | 47.5B | 61.75 | 7.63 | 14.06% | 27.34% | 1.24 |
Ge Healthcare | 33.4B | 14.99 | 3.44 | 25.80% | 11.22% | 107.67 |
10x Genomics | 1.8B | -9.41 | 2.30 | -11.30% | -13.13% | 11.22 |
Certara | 1.8B | 220.30 | 1.65 | 0.75% | 1.97% | 29.00 |
GoodRx Holdings | 1.6B | 49.89 | 2.43 | 5.27% | 4.33% | 85.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.